Sequential activation of Elk-1/Egr-1/GADD45α by arsenic

Qiwen Shi; Vijaykumar Sutariya; Anupam Bishayee; Deepak Bhatia

doi:10.18632/oncotarget.1995

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Sequential activation of Elk-1/Egr-1/GADD45α by arsenic

Qiwen Shi, Vijaykumar Sutariya, Anupam Bishayee and Deepak Bhatia _

PDF | HTML | How to cite

Oncotarget. 2014; 5:3862-3870. https://doi.org/10.18632/oncotarget.1995

Metrics: PDF 1983 views | HTML 2857 views | ?

Abstract

Qiwen Shi1,2, Vijaykumar Sutariya3, Anupam Bishayee4 and Deepak Bhatia1

1 Department of Pharmaceutical Sciences, Northeast Ohio Medical University (NEOMED), Rootstown, Ohio, USA

2 School of Biomedical Sciences, Kent State University, Kent, Ohio, USA

3 Department of Pharmaceutical Sciences, University of South Florida, Tampa, Florida, USA

4 Department of Pharmaceutical Sciences, American University of Health Sciences, Signal Hill, California, USA

Correspondence:

Deepak Bhatia, email:

Keywords: Egr-1; GADD45α; Arsenic; MAP kinase; Elk-1

Received: February 14, 2014 Accepted: May 20, 2014 Published: May 22, 2014

Abstract

Long-term exposure to arsenic, an environmental contaminant, leads to increased risks of cancers. In the present study, we investigated the sequential regulation of Elk-1 and Egr-1 on As3+-induced GADD45α, an effector of G2/M checkpoint. We found that As3+ transcriptionally induced both Elk-1 and Egr-1, and NF-κB binding site was necessary for As3+-induced Egr-1 promoter activity. However, specific inhibition of JNK, ERK, and Elk-1 inhibited Egr-1 induction. Furthermore, silencing of Egr-1 downregulated As3+-induced expression of GADD45α and ChIP assay confirmed the direct binding of Egr-1 to GADD45α promoter. Taken together, our data indicated that the increase of GADD45α in response to As3+ was mediated sequentially by Elk-1 and Egr-1.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 1995

Publication Alerts

Research Papers:

Sequential activation of Elk-1/Egr-1/GADD45α by arsenic

Abstract